Daniel Peterson
Family · Salt Lake City, UTNPI 1194411355
Payments from drug & device makers
Across 155 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Xeris Pharmaceuticals, Inc.$338
- Lilly USA, LLC$307
- Novo Nordisk$229
- BETA Bionics, Inc.$195
- Ascensia Diabetes Care US Inc.$190
- plus $1K from 18 others
What the payments were for
- Travel & lodging$81421%
- Food & beverage$3,04179%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $1,212 |
| Xeris Pharmaceuticals, Inc. | 19 | $338 |
| Lilly USA, LLC | 16 | $307 |
| Novo Nordisk | 13 | $229 |
| BETA Bionics, Inc. | 10 | $195 |
| Ascensia Diabetes Care US Inc. | 10 | $190 |
| Amgen | 10 | $177 |
| Sanofi-aventis U.S. LLC | 9 | $163 |
| AbbVie | 9 | $157 |
| Tandem Diabetes Care, Inc. | 6 | $131 |
| Dexcom, Inc. | 6 | $120 |
| Kyowa Kirin, Inc. | 1 | $107 |
| Bayer | 4 | $67 |
| Radius Health, Inc. | 3 | $64 |
| Neurocrine Biosciences, Inc. | 2 | $60 |
| Ascendis Pharma Endocrinology Inc | 3 | $59 |
| Boston Scientific | 3 | $59 |
| Corcept Therapeutics | 3 | $58 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Recordati_rare_diseases_inc. | 2 | $48 |
| Novartis | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Antares Pharma, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$805
- CRYSVITA$107
How this compares
$3,863 in reported general payments places this provider in the 90th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 33 | $62,395 |
| OzempicSemaglutide | 44 | $52,123 |
| JardianceEmpagliflozin | 40 | $45,485 |
| TrulicityDulaglutide | 22 | $29,819 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 17 | $8,153 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,350 |
| SynthroidLevothyroxine Sodium | 22 | $2,500 |
| Liothyronine Sodium | 43 | $1,692 |
| Testosterone Cypionate | 27 | $1,124 |
| Levothyroxine Sodium | 97 | $909 |
| Metformin Hcl | 44 | $518 |
| Methimazole | 15 | $204 |
| Pioglitazone Hcl | 22 | $170 |
| Metformin Hcl ErMetformin Hcl | 18 | $147 |
| Atorvastatin Calcium | 17 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $307 | $92,21455 claims |
| Novo NordiskOzempic | $229 | $52,12344 claims |
| AbbVieSynthroid | $157 | $2,50022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,460 family providers in Utah.
Other family in Salt Lake City
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Kacie Doyle-DelgadoSalt Lake City$80K
- Melonie ThompsonSalt Lake City$45K
- Michelle LitchmanSalt Lake City$44K
- Keisa LynchSalt Lake City$39K
- Christina CardonSalt Lake City$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.